Abstract
Use of highly active antiretroviral therapy has resulted in significant reductions in HIV-related morbidity and mortality. Current therapeutic approaches target cellular entry, viral transcription, and maturation of newly formed virus. Combination therapy is necessary to provide durable suppression of viral replication and immune reconstitution. A variety of consensus treatment guidelines addressing prophylaxis and treatment of HIV infection and opportunistic infections have been developed to serve as resources for clinicians. A summary of U.S. Department of Health and Human Services Guidelines for Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents and International AIDS Society- USA Panel recommendations for Treatment of Adult HIV infection are presented. Considerations for selection of antiretroviral therapy in special populations (e.g., pregnancy, coinfection with tuberculosis, hepatitis B and C virus) are highlighted. U.S. Public Health Service guidelines for management of occupational exposure to HIV and initiation of postexposure prophylaxis are discussed as well as World Health Organization recommendations for use of antiretroviral therapy in resource-limited settings. The pathophysiology of HIV infection, viral load testing methods, viral dynamics, and classification of antiretrovirals are also briefly reviewed.
Keywords: HIV infection, antiretroviral therapy, treatment guidelines
Current Pharmaceutical Design
Title: Current HIV Treatment Guidelines - An Overview
Volume: 12 Issue: 9
Author(s): R. C. Rathbun, S. M. Lockhart and J. R. Stephens
Affiliation:
Keywords: HIV infection, antiretroviral therapy, treatment guidelines
Abstract: Use of highly active antiretroviral therapy has resulted in significant reductions in HIV-related morbidity and mortality. Current therapeutic approaches target cellular entry, viral transcription, and maturation of newly formed virus. Combination therapy is necessary to provide durable suppression of viral replication and immune reconstitution. A variety of consensus treatment guidelines addressing prophylaxis and treatment of HIV infection and opportunistic infections have been developed to serve as resources for clinicians. A summary of U.S. Department of Health and Human Services Guidelines for Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents and International AIDS Society- USA Panel recommendations for Treatment of Adult HIV infection are presented. Considerations for selection of antiretroviral therapy in special populations (e.g., pregnancy, coinfection with tuberculosis, hepatitis B and C virus) are highlighted. U.S. Public Health Service guidelines for management of occupational exposure to HIV and initiation of postexposure prophylaxis are discussed as well as World Health Organization recommendations for use of antiretroviral therapy in resource-limited settings. The pathophysiology of HIV infection, viral load testing methods, viral dynamics, and classification of antiretrovirals are also briefly reviewed.
Export Options
About this article
Cite this article as:
Rathbun C. R., Lockhart M. S. and Stephens R. J., Current HIV Treatment Guidelines - An Overview, Current Pharmaceutical Design 2006; 12(9) . https://dx.doi.org/10.2174/138161206776055840
| DOI https://dx.doi.org/10.2174/138161206776055840 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Functional Gene Discovery Using RNA Interference-Based Genomic Screens to Combat Pathogen Infection
Current Drug Discovery Technologies Recent Patents on Oral Combination Drug Delivery and Formulations
Recent Patents on Drug Delivery & Formulation The Battle for Iron between Humans and Microbes
Current Medicinal Chemistry Response to HAART in Treatment-Naive HIV-Infected Patients with a Prior Diagnosis of Tuberculosis or other Opportunistic Infections
Current HIV Research Transcription Analysis and Small Non-Protein Coding RNAs Associated with Bacterial Ribosomal Protein Operons
Current Medicinal Chemistry Resistant TB: Newer Drugs and Community Approach
Recent Patents on Anti-Infective Drug Discovery Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization
Current Pharmaceutical Design Positron Emission Tomography in the Diagnosis and Treatment Management of Tuberculosis
Current Pharmaceutical Design Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World
Current Pharmaceutical Design Anti-Mycobacterial Activity of Quinolones. Triazoloquinolones a New Class of Potent Anti-Mycobacterial Agents
Anti-Infective Agents in Medicinal Chemistry Structure and Function of RNase AS: A Novel Virulence Factor From Mycobacterium tuberculosis
Current Medicinal Chemistry Harnessing the Prevention Benefits of Antiretroviral Therapy to Address HIV and Tuberculosis
Current HIV Research Microsphere Technology for Chemotherapy of Mycobacterial Infections
Current Pharmaceutical Design Medicinal Chemistry Discoveries among 1,3,5-Triazines: Recent Advances (2000-2013) as Antimicrobial, Anti-TB, Anti-HIV and Antimalarials
Mini-Reviews in Medicinal Chemistry Recent Highlights on the Synthesis of Pyrazoles with Antimicrobial Activity
Current Bioactive Compounds Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy Targeting the Mannose Receptor with Mannosylated Subunit Vaccines
Current Medicinal Chemistry Drug Design and Identification of Potent Leads Against Mycobacterium tuberculosis Thymidine Monophosphate Kinase
Current Topics in Medicinal Chemistry QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB
Current Pharmaceutical Design The Mode of Inhibition of Mycobacterium tuberculosis Wild-Type and Isoniazid-Resistant 2-Trans-Enoyl-ACP(CoA) Reductase Enzymes by An Inorganic Complex
Anti-Infective Agents in Medicinal Chemistry




